Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Next Deadline
61 days remaining
NOA E-Mailed - SOU Required
Due Date
February 20, 2026
Extension Available
Until August 20, 2026
Application History
29 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 26, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 25, 2025 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Aug 25, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Aug 11, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Aug 25, 2025 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| May 8, 2025 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| May 8, 2025 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Aug 12, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 11, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Feb 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 20, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Feb 19, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Feb 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 19, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 19, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Aug 19, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 19, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 20, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 26, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 26, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 6, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 17, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 17, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Nov 17, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Nov 17, 2023 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Nov 17, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Nov 14, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 6, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 18, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; biotherapeutics for the treatment and prevention of inflammation and inflammatory diseases; medicines for the treatment and prevention of inflammation and inflammatory diseases; pharmaceutical products for the treatment and prevention of inflammation and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of inflammation and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of inflammation and inflammatory diseases; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of inflammation and inflammatory diseases; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases
Class 040
Manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of inflammation and inflammatory diseases using biological cells in the manufacturing process; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of inflammation and inflammatory disease
Class 042
Identification and development of therapeutic targets for others for the treatment and prevention of inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of inflammation, and inflammatory diseases; providing scientific information relating to treatment and prevention of inflammation and inflammatory diseases
Additional Information
Pseudo Mark
A TWO BIO
Classification
International Classes
005
040
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIO"